Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06229860 · ClinicalTrials.gov registry record
Impact of Personality on Adherence to Tyrosine Kinase Inhibitor Therapy in Pts w/Chronic Myeloid Leukemia
A clinical trial of Chronic Myeloid Leukemia and Chronic Phase Chronic Myelogenous Leukemia, sponsored by University of California, Irvine.
- Recruiting
- Registry status
- 75
- Enrollment target
- 1
- Study location
NCT06229860 is a study of Chronic Myeloid Leukemia and Chronic Phase Chronic Myelogenous Leukemia that is actively recruiting participants, run by University of California, Irvine. The registered enrollment target is 75 participants, below the 208-participant average among 35 other Chronic Myeloid Leukemia trials with a reported enrollment target (64% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06229860, a study of Chronic Myeloid Leukemia and Chronic Phase Chronic Myelogenous Leukemia, is actively recruiting participants, sponsored by University of California, Irvine.
- RECRUITING
- Registry status
- 75 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an observational pilot study to examine the association between a patient's personality and adherence to tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia.
Conditions Studied
Interventions
- OTHER Interview
Study Locations (1)
California
- Chao Family Comprehensive Cancer Center University of California, Irvine - Orange
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2024-01-25 |
| Est. Completion | 2026-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06229860
The ClinicalTrials.gov registry entry for NCT06229860 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 208-participant average among 35 other Chronic Myeloid Leukemia trials with a reported enrollment target (64% lower). The listed sponsor is University of California, Irvine, which has 368 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Chronic Myeloid Leukemia appearing as the primary indexed condition, and to 1 intervention - of which Interview is the first listed.
NCT06229860 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT06229860 about?
NCT06229860 is a clinical study titled "Impact of Personality on Adherence to Tyrosine Kinase Inhibitor Therapy in Pts w/Chronic Myeloid Leukemia". This is an observational pilot study to examine the association between a patient's personality and adherence to tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia.
What is the current status of trial NCT06229860?
This trial is currently recruiting. The enrollment target is 75 participants. The study started on 2024-01-25. Estimated completion is 2026-12.
What conditions does trial NCT06229860 study?
This clinical trial studies the following conditions: Chronic Myeloid Leukemia, Chronic Phase Chronic Myelogenous Leukemia.
What interventions are being tested in trial NCT06229860?
The interventions under investigation include: Interview (OTHER).
Who is sponsoring clinical trial NCT06229860?
This trial is sponsored by University of California, Irvine, which has 368 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06229860 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Myeloid Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
RECRUITING · Phase 1
-
Study of Olverembatinib (HQP1351) in Patients With CP-CML
RECRUITING · Phase 3
-
Safety And Efficacy Of TKI Cessation For CML Patients With Stable Molecular Response In A Real World Population
RECRUITING · Phase 2
-
KRT-232 and TKI Study in Chronic Myeloid Leukemia
RECRUITING · Phase 1
-
A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia
RECRUITING · Phase 1
-
Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
RECRUITING · Phase 2
Explore more on PlainTrial
Chronic Myeloid Leukemia
All registered trials for this condition
Chronic Phase Chronic Myelogenous Leukemia
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.